Abstract
BackgroundPremature ovarian insufficiency (POI) is an ovarian defect characterized by primary or secondary amenorrhea, hypergonadotropism and hypoestrogenism which occurs before the age of 40 years with a major genetic component. In this study we performed clinical evaluation and genetic analysis of a group of 18 patients with POI.The study involved 18 consecutive women with POI. Karyotiping and genetic analysis for research of mutations in GDF9 (Growth Differentation Factor 9) and BMP15 (Bone morphogentic protein 15) genes and FMR1 (Fragile X Mental Retardation 1) premutation were carried out. In vitro functional study of the novel BMP15 mutation was performed using COV434 (Human ovarian granulosa tumour cells 434) cells of ovarian granulosa, which consistently express BMP responsive element, and luciferase reporter assay.ResultsThree patients (17%) had a family history of POI. Ten patients (56%) had a family history of autoimmune diseases and nine patients (50%) showed a personal history of one or more autoimmune diseases. Of patients for whom morphological assessment was available, almost half (44%) had poor follicle assets or small ovaries’s size at pelvic US. Two patients (13%) showed reduced bone density at DEXA (Dual Energy X-ray Absorptiometry). All the women had normal female kariotype and no mutations in the GDF-9 gene or FMR1 premutations were found. A novel heterozygous mutation c.406G > C (V136L) of BMP15 gene was identified in one patient. After transfection in COV434 cells, BMP15 variant showed a significantly reduced luciferase activity compared to wild type.ConclusionsPOI is a multifactorial disease with several health implications. Autoimmunity and genetics represent the most common aetiology. We identified and characterized a novel BMP15 mutation, providing an additional elucidation of molecular basis of this complex disorder.
Highlights
Premature Ovariane failure (POI) is defined as a primary ovarian defect characterized by absent menarche or premature depletion of ovarianPremature ovarian insufficiency (POI) affects approximately 0.01% of women aged under 20 years, 0.1% of women aged under 30 yeras and 1% women aged under 40 years [2].The aetiology of POI is highly heterogeneous, with a wide spectrum of causes, namely cytogenetic, genetic, autoimmune, infectious or iatrogenic, but often the cause remainsFerrarini et al J Ovarian Res (2021) 14:85 unknown
A novel heterozygous mutation c.406G > C (V136L) of BMP15 gene was identified in one patient
After transfection in Human ovarian granulosa tumour cells 434 (COV434) cells, BMP15 variant showed a significantly reduced luciferase activity compared to wild type
Summary
Premature Ovariane failure (POI) is defined as a primary ovarian defect characterized by absent menarche (primary amenorrhea) or premature depletion of ovarianPOI affects approximately 0.01% of women aged under 20 years, 0.1% of women aged under 30 yeras and 1% women aged under 40 years [2].The aetiology of POI is highly heterogeneous, with a wide spectrum of causes, namely cytogenetic, genetic, autoimmune, infectious or iatrogenic (chemiotherapy, radiotherapy, surgery), but often the cause remainsFerrarini et al J Ovarian Res (2021) 14:85 unknown. Factors synthesised by the oocyte or surrounding granulosa cells, such as growth differentiation factor 9, GDF9 (MIM# 601,919), and bone morphogenetic protein 15, BMP-15 (MIM# 300,247), are the primary drivers of early follicle development. They are soluble growth factors, members of the transforming growth factor β superfamily, localized on 5q.31.1 and Xp11.2 (POI region) respectively and are coexpressed in mammalian oocytes. Karyotiping and genetic analysis for research of mutations in GDF9 (Growth Differentation Factor 9) and BMP15 (Bone morphogentic protein 15) genes and FMR1 (Fragile X Mental Retardation 1) premutation were carried out. In vitro functional study of the novel BMP15 mutation was performed using COV434 (Human ovarian granulosa tumour cells 434) cells of ovarian granulosa, which consistently express BMP responsive element, and luciferase reporter assay
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.